However, metformin (5 mM) treatment suppressed the BRCA1 haploinsufficiency-driven overexpression of RANK-L and synergistically reduced the self-renewal capacity in BRCA1-mutated basal-like breast cancer cells, resulting in a decrease in the breast cancer-initiating cell population [274]. The gene discussed is BRCA1; the disease is breast carcinoma.